{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:56:46Z","timestamp":1791284206316,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s13555-025-01351-z","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T19:35:08Z","timestamp":1739561708000},"page":"599-613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Child and Adult Seborrheic Dermatitis: A Narrative Review of the Current Treatment Landscape"],"prefix":"10.1007","volume":"15","author":[{"given":"Savanna I.","family":"Vidal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Menta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"issue":"5","key":"1351_CR1","first-page":"32","volume":"4","author":"JQ Del Rosso","year":"2011","unstructured":"Del Rosso JQ. Adult seborrheic dermatitis: a status report on practical topical management. J Clin Aesthet Dermatol. 2011;4(5):32\u20138.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"8","key":"1351_CR2","doi-asserted-by":"publisher","first-page":"e27622","DOI":"10.7759\/cureus.27622","volume":"14","author":"O Alsmeirat","year":"2022","unstructured":"Alsmeirat O, Lakhani S, Egaimi M, Idris O, Elkhalifa M. The efficacy and safety of pimecrolimus in patients with facial seborrheic dermatitis: a systematic review of randomized controlled trials. Cureus. 2022;14(8):e27622. https:\/\/doi.org\/10.7759\/cureus.27622.","journal-title":"Cureus"},{"issue":"5","key":"1351_CR3","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1111\/jocd.14362","volume":"21","author":"P Massiot","year":"2022","unstructured":"Massiot P, Clavaud C, Thomas M, et al. Continuous clinical improvement of mild-to-moderate seborrheic dermatitis and rebalancing of the scalp microbiome using a selenium disulfide-based shampoo after an initial treatment with ketoconazole. J Cosmet Dermatol. 2022;21(5):2215\u201325. https:\/\/doi.org\/10.1111\/jocd.14362.","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"1351_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40266-022-00930-5","volume":"39","author":"J Sowell","year":"2022","unstructured":"Sowell J, Pena SM, Elewski BE. Seborrheic dermatitis in older adults: pathogenesis and treatment options. Drugs Aging. 2022;39(5):315\u201321. https:\/\/doi.org\/10.1007\/s40266-022-00930-5.","journal-title":"Drugs Aging"},{"issue":"12","key":"1351_CR5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.36849\/JDD.1022","volume":"21","author":"S Desai","year":"2022","unstructured":"Desai S, McCormick E, Friedman A. An up-to-date approach to the management of seborrheic dermatitis. J Drugs Dermatol. 2022;21(12):1373\u20134. https:\/\/doi.org\/10.36849\/JDD.1022.","journal-title":"J Drugs Dermatol"},{"issue":"S1","key":"1351_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1684\/ejd.2024.4703","volume":"34","author":"S Vano-Galvan","year":"2024","unstructured":"Vano-Galvan S, Reygagne P, Melo DF, et al. A comprehensive literature review and an international expert consensus on the management of scalp seborrheic dermatitis in adults. Eur J Dermatol. 2024;34(S1):4\u201316. https:\/\/doi.org\/10.1684\/ejd.2024.4703.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"1351_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/09546634.2018.1473554","volume":"30","author":"LJ Borda","year":"2019","unstructured":"Borda LJ, Perper M, Keri JE. Treatment of seborrheic dermatitis: a comprehensive review. J Dermatol Treat. 2019;30(2):158\u201369. https:\/\/doi.org\/10.1080\/09546634.2018.1473554.","journal-title":"J Dermatol Treat"},{"key":"1351_CR8","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.2147\/CCID.S284671","volume":"15","author":"F Dall\u2019Oglio","year":"2022","unstructured":"Dall\u2019Oglio F, Nasca MR, Gerbino C, Micali G. An overview of the diagnosis and management of seborrheic dermatitis. Clin Cosmet Investig Dermatol. 2022;15:1537\u201348. https:\/\/doi.org\/10.2147\/CCID.S284671.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"9","key":"1351_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3390\/jpm12091540","volume":"12","author":"SR Georgescu","year":"2022","unstructured":"Georgescu SR, Mitran CI, Mitran MI, Amuzescu A, Matei C, Tampa M. A meta-analysis on the effectiveness of sertaconazole 2% cream compared with other topical therapies for seborrheic dermatitis. J Pers Med. 2022;12(9):1540. https:\/\/doi.org\/10.3390\/jpm12091540.","journal-title":"J Pers Med"},{"issue":"8","key":"1351_CR10","doi-asserted-by":"publisher","first-page":"e67532","DOI":"10.7759\/cureus.67532","volume":"16","author":"BE Tynes","year":"2024","unstructured":"Tynes BE, Johnson CD, Vaish MH, et al. Ketoconazole shampoo for seborrheic dermatitis of the scalp: a narrative review. Cureus. 2024;16(8):e67532. https:\/\/doi.org\/10.7759\/cureus.67532.","journal-title":"Cureus"},{"key":"1351_CR11","doi-asserted-by":"publisher","first-page":"CD008138","DOI":"10.1002\/14651858.CD008138.pub3","volume":"5","author":"EO Okokon","year":"2015","unstructured":"Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrheic dermatitis. Cochrane Database Syst Rev. 2015;5:CD008138. https:\/\/doi.org\/10.1002\/14651858.CD008138.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1351_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s13555-019-00339-w","volume":"10","author":"A Balato","year":"2020","unstructured":"Balato A, Caiazzo G, Di Caprio R, Scala E, Fabbrocini G, Granger C. Exploring anti-fungal, anti-microbial and anti-inflammatory properties of a topical non-steroidal barrier cream in face and chest seborrheic dermatitis. Dermatol Ther (Heidelb). 2020;10(1):87\u201398. https:\/\/doi.org\/10.1007\/s13555-019-00339-w.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1351_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fcimb.2020.00191","volume":"10","author":"M Park","year":"2020","unstructured":"Park M, Cho YJ, Lee YW, Jung WH. Genomic multiplication and drug efflux influence ketoconazole resistance in Malassezia restricta. Front Cell Infect Microbiol. 2020;10:191. https:\/\/doi.org\/10.3389\/fcimb.2020.00191.","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"1351_CR14","doi-asserted-by":"publisher","first-page":"e01975","DOI":"10.1128\/AAC.01975-20","volume":"65","author":"C Leong","year":"2021","unstructured":"Leong C, Kit JCW, Lee SM, et al. Azole resistance mechanisms in pathogenic M. furfur. Antimicrob Agents Chemother. 2021;65(5):e01975-e2020. https:\/\/doi.org\/10.1128\/AAC.01975-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1351_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2340\/00015555-1825","volume":"95","author":"M Hald","year":"2015","unstructured":"Hald M, Arendrup MC, Svejgaard EL, et al. Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases. Acta Derm Venereol. 2015;95(1):12\u20139. https:\/\/doi.org\/10.2340\/00015555-1825.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"1351_CR16","doi-asserted-by":"publisher","first-page":"e70335","DOI":"10.7759\/cureus.70335","volume":"16","author":"RM Alofi","year":"2024","unstructured":"Alofi RM, Alrohaily LS, Alharthi NN, Almouteri MM. Ocular manifestations in seborrheic dermatitis epidemiology, clinical features, and management: a comprehensive review. Cureus. 2024;16(9):e70335. https:\/\/doi.org\/10.7759\/cureus.70335.","journal-title":"Cureus"},{"issue":"3","key":"1351_CR17","first-page":"185","volume":"91","author":"GW Clark","year":"2015","unstructured":"Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015;91(3):185\u201390.","journal-title":"Am Fam Physician"},{"issue":"5","key":"1351_CR18","doi-asserted-by":"publisher","first-page":"CD009446","DOI":"10.1002\/14651858.CD009446.pub2","volume":"2014","author":"H Kastarinen","year":"2014","unstructured":"Kastarinen H, Oksanen T, Okokon EO, et al. Topical anti-inflammatory agents for seborrheic dermatitis of the face or scalp. Cochrane Database Syst Rev. 2014;2014(5):CD009446. https:\/\/doi.org\/10.1002\/14651858.CD009446.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1351_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/00015550510040040","volume":"86","author":"PR Cunha","year":"2006","unstructured":"Cunha PR. Pimecrolimus cream 1% is effective in seborrheic dermatitis refractory to treatment with topical corticosteroids. Acta Derm Venereol. 2006;86(1):69\u201370. https:\/\/doi.org\/10.1080\/00015550510040040.","journal-title":"Acta Derm Venereol"},{"issue":"4_suppl","key":"1351_CR20","doi-asserted-by":"publisher","first-page":"27S","DOI":"10.1177\/1203475419857668","volume":"23","author":"L Guenther","year":"2019","unstructured":"Guenther L, Lynde C, Poulin Y. Off-label use of topical calcineurin inhibitors in dermatologic disorders. J Cutan Med Surg. 2019;23(4_suppl):27S-34S. https:\/\/doi.org\/10.1177\/1203475419857668.","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"1351_CR21","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/ced.15067","volume":"47","author":"M Azizzadeh","year":"2022","unstructured":"Azizzadeh M, Pahlevan D, Bagheri B. The efficacy and safety of pimecrolimus 1% cream vs. sertaconazole 2% cream in the treatment of patients with facial seborrheic dermatitis: a randomized blinded trial. Clin Exp Dermatol. 2022;47(5):926\u201331. https:\/\/doi.org\/10.1111\/ced.15067.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1351_CR22","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jaad.2020.09.055","volume":"84","author":"P Joly","year":"2021","unstructured":"Joly P, Tejedor I, Tetart F, et al. Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: a multicenter, double-blind, randomized controlled study. J Am Acad Dermatol. 2021;84(5):1278\u201384. https:\/\/doi.org\/10.1016\/j.jaad.2020.09.055.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1351_CR23","first-page":"24","volume":"18","author":"M Elgash","year":"2019","unstructured":"Elgash M, Dlova N, Ogunleye T, Taylor SC. Seborrheic dermatitis in skin of color: clinical considerations. J Drugs Dermatol. 2019;18(1):24\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1351_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2340\/00015555-1532","volume":"93","author":"TW Kim","year":"2013","unstructured":"Kim TW, Mun JH, Jwa SW, et al. Proactive treatment of adult facial seborrheic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial. Acta Derm Venereol. 2013;93(5):557\u201361. https:\/\/doi.org\/10.2340\/00015555-1532.","journal-title":"Acta Derm Venereol"},{"key":"1351_CR25","unstructured":"Bader K. FDA approves roflumilast cream 0.15% for atopic dermatitis in patients aged 6\u00a0years and older. Dermatology Times. 2024. https:\/\/www.dermatologytimes.com\/view\/fda-approves-roflumilast-cream-0-15-for-atopic-dermatitis-in-patients-aged-6-years-and-older."},{"issue":"6","key":"1351_CR26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamadermatol.2023.0846","volume":"159","author":"MJ Zirwas","year":"2023","unstructured":"Zirwas MJ, Draelos ZD, DuBois J, et al. Efficacy of roflumilast foam, 0.3%, in patients with seborrheic dermatitis: a double-blind, vehicle-controlled phase\u00a02a randomized clinical trial. JAMA Dermatol. 2023;159(6):613\u201320. https:\/\/doi.org\/10.1001\/jamadermatol.2023.0846.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1351_CR27","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jaad.2023.12.065","volume":"90","author":"A Blauvelt","year":"2024","unstructured":"Blauvelt A, Draelos ZD, Stein Gold L, et al. Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: a randomized, double-blinded, vehicle-controlled, phase\u00a03 trial. J Am Acad Dermatol. 2024;90(5):986\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2023.12.065.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1351_CR28","first-page":"30","volume":"17","author":"R Chovatiya","year":"2024","unstructured":"Chovatiya R, Polaskey MT, Lain E, et al. Putting the formulation back in foam: optimizing seborrheic dermatitis treatment across diverse hair types. J Clin Aesthet Dermatol. 2024;17(5):30\u20133.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"12","key":"1351_CR29","doi-asserted-by":"publisher","first-page":"e809","DOI":"10.1111\/jdv.16673","volume":"34","author":"SM Pe\u00f1a","year":"2020","unstructured":"Pe\u00f1a SM, Oak ASW, Smith AM, Mayo TT, Elewski BE. Topical crisaborole is an efficacious steroid-sparing agent for treating mild-to-moderate seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2020;34(12):e809\u201312. https:\/\/doi.org\/10.1111\/jdv.16673.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1351_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jdcr.2022.04.003","volume":"24","author":"E Pope","year":"2022","unstructured":"Pope E, Kowalski E, Tausk F. Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis. JAAD Case Rep. 2022;24:59\u201360. https:\/\/doi.org\/10.1016\/j.jdcr.2022.04.003.","journal-title":"JAAD Case Rep"},{"key":"1351_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jdcr.2023.09.038","volume":"42","author":"M Teklu","year":"2023","unstructured":"Teklu M, Chung HJ. Letter in response to the case report \u201cTopical ruxolitinib in the treatment of refractory facial seborrheic dermatitis.\u201d JAAD Case Rep. 2023;42:45\u20136. https:\/\/doi.org\/10.1016\/j.jdcr.2023.09.038.","journal-title":"JAAD Case Rep"},{"key":"1351_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/12034754241290826","author":"S Sood","year":"2024","unstructured":"Sood S, Perlmutter J, Maliyar K, Abduelmula A, Mufti A, Yeung J. Biologic and small molecule treatment for seborrheic dermatitis: an evidence-based review. J Cutan Med Surg. 2024. https:\/\/doi.org\/10.1177\/12034754241290826.","journal-title":"J Cutan Med Surg"},{"key":"1351_CR33","doi-asserted-by":"publisher","first-page":"adv12343","DOI":"10.2340\/actadv.v103.12343","volume":"103","author":"NT Issa","year":"2023","unstructured":"Issa NT, Kaiser M. First use of tapinarof monotherapy for seborrhoeic dermatitis: a case report. Acta Derm Venereol. 2023;103:adv12343. https:\/\/doi.org\/10.2340\/actadv.v103.12343.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1351_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5114\/ada.2019.82825","volume":"36","author":"W Bara\u0144ska-Rybak","year":"2019","unstructured":"Bara\u0144ska-Rybak W, Kowalska-Ol\u0119dzka E. New indications for topical ivermectin 1% cream: a case series study. Postepy Dermatol Alergol. 2019;36(1):58\u201362. https:\/\/doi.org\/10.5114\/ada.2019.82825.","journal-title":"Postepy Dermatol Alergol"},{"issue":"2","key":"1351_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40257-016-0232-2","volume":"18","author":"AK Gupta","year":"2017","unstructured":"Gupta AK, Versteeg SG. Topical treatment of facial seborrheic dermatitis: a systematic review. Am J Clin Dermatol. 2017;18(2):193\u2013213. https:\/\/doi.org\/10.1007\/s40257-016-0232-2.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1351_CR36","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000539209","volume":"10","author":"V Barbosa","year":"2024","unstructured":"Barbosa V, Melo DF, Va\u00f1\u00f3-Galv\u00e1n S, et al. A Comparative randomized clinical study assessing the efficacy of a 1% selenium disulfide-based shampoo versus 2% ketoconazole shampoo in subjects with moderate to severe scalp seborrheic dermatitis. Skin Appendage Disord. 2024;10(6):497\u2013504. https:\/\/doi.org\/10.1159\/000539209.","journal-title":"Skin Appendage Disord"},{"issue":"5","key":"1351_CR37","first-page":"40","volume":"16","author":"S Hasanbeyzade","year":"2023","unstructured":"Hasanbeyzade S. The effects of zinc pyrithione and selenium disulfide shampoos on the lesion-free period after treatment in patients with seborrheic dermatitis. J Clin Aesthet Dermatol. 2023;16(5):40\u20132.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"3","key":"1351_CR38","doi-asserted-by":"publisher","first-page":"e57148","DOI":"10.7759\/cureus.57148","volume":"16","author":"G Godse","year":"2024","unstructured":"Godse G, Godse K. Safety, efficacy and attributes of 2.5% selenium sulfide shampoo in the treatment of dandruff: a single-center study. Cureus. 2024;16(3):e57148. https:\/\/doi.org\/10.7759\/cureus.57148.","journal-title":"Cureus"},{"key":"1351_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejpb.2023.01.023","volume":"185","author":"SE Mangion","year":"2023","unstructured":"Mangion SE, Mackenzie L, Roberts MS, Holmes AM. Seborrheic dermatitis: topical therapeutics and formulation design. Eur J Pharm Biopharm. 2023;185:148\u201364. https:\/\/doi.org\/10.1016\/j.ejpb.2023.01.023.","journal-title":"Eur J Pharm Biopharm"},{"key":"1351_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.16617","author":"Q Wang","year":"2024","unstructured":"Wang Q, Liu Y, Ye C, et al. SSA-ZP on scalp seborrheic dermatitis: regulating sebum levels and scalp barrier. J Cosmet Dermatol. 2024. https:\/\/doi.org\/10.1111\/jocd.16617.","journal-title":"J Cosmet Dermatol"},{"issue":"9","key":"1351_CR41","doi-asserted-by":"publisher","first-page":"e70108","DOI":"10.7759\/cureus.70108","volume":"16","author":"MN Patel","year":"2024","unstructured":"Patel MN, Patel N, Merja A, Patnaik S. An assessment of the safety, efficacy, and tolerability of a novel scalp treatment regimen combining a hydroxy acid-based scrub and copper tripeptide serum in the management of seborrheic dermatitis in adults. Cureus. 2024;16(9):e70108. https:\/\/doi.org\/10.7759\/cureus.70108.","journal-title":"Cureus"},{"issue":"8","key":"1351_CR42","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1111\/jocd.14623","volume":"21","author":"HC Wang","year":"2022","unstructured":"Wang HC, Wang CS, Hsieh SC, Hung YT, Chen HH. Evaluation of a new-formula shampoo containing 6% glycyrrhetinic acid complex for scalp seborrheic dermatitis: a pilot study. J Cosmet Dermatol. 2022;21(8):3423\u201330. https:\/\/doi.org\/10.1111\/jocd.14623.","journal-title":"J Cosmet Dermatol"},{"issue":"6","key":"1351_CR43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000510896","volume":"6","author":"C Vincenzi","year":"2020","unstructured":"Vincenzi C, Tosti A. Efficacy and tolerability of a shampoo containing broad-spectrum cannabidiol in the treatment of scalp inflammation in patients with mild to moderate scalp psoriasis or seborrheic dermatitis. Skin Appendage Disord. 2020;6(6):355\u201361. https:\/\/doi.org\/10.1159\/000510896.","journal-title":"Skin Appendage Disord"},{"key":"1351_CR44","doi-asserted-by":"publisher","first-page":"e50143","DOI":"10.2196\/50143","volume":"7","author":"E Woolhiser","year":"2024","unstructured":"Woolhiser E, Keime N, Patel A, Weber I, Adelman M, Dellavalle RP. Nutrition, obesity, and seborrheic dermatitis: systematic review. JMIR Dermatol. 2024;7:e50143. https:\/\/doi.org\/10.2196\/50143.","journal-title":"JMIR Dermatol"},{"issue":"5","key":"1351_CR45","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1111\/1751-7915.13897","volume":"14","author":"R Yu","year":"2021","unstructured":"Yu R, Lin Q, Zhai Y, et al. Recombinant human thymosin beta-4 (rhT\u03b24) improved scalp condition and microbiome homeostasis in seborrheic dermatitis. Microb Biotechnol. 2021;14(5):2152\u201363. https:\/\/doi.org\/10.1111\/1751-7915.13897.","journal-title":"Microb Biotechnol"},{"key":"1351_CR46","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2147\/CCID.S231313","volume":"12","author":"E Campione","year":"2019","unstructured":"Campione E, Mazzilli S, Lanna C, et al. The effectiveness of a new topical formulation containing GSH-C4 and hyaluronic acid in seborrheic dermatitis: preliminary results of an exploratory pilot study. Clin Cosmet Investig Dermatol. 2019;12:881\u20135. https:\/\/doi.org\/10.2147\/CCID.S231313.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1351_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2147\/CCID.S219109","volume":"13","author":"S Sadhasivam","year":"2020","unstructured":"Sadhasivam S, Garkhal K, Singh H, et al. Newly developed anti-dandruff regimen, VB-3222, delivers enhanced sensorial and effective therapeutic benefits against moderate adherent dandruff. Clin Cosmet Investig Dermatol. 2020;13:187\u201395. https:\/\/doi.org\/10.2147\/CCID.S219109.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"1351_CR48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/jdv.12197","volume":"28","author":"AK Gupta","year":"2014","unstructured":"Gupta AK, Richardson M, Paquet M. Systematic review of oral treatments for seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2014;28(1):16\u201326. https:\/\/doi.org\/10.1111\/jdv.12197.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1351_CR49","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/09546634.2019.1708242","volume":"32","author":"Y Wang","year":"2021","unstructured":"Wang Y, Lipner SR. Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration. J Dermatol Treat. 2021;32(7):783\u20137. https:\/\/doi.org\/10.1080\/09546634.2019.1708242.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"1351_CR50","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2165\/00128071-200405060-00006","volume":"5","author":"AK Gupta","year":"2004","unstructured":"Gupta AK, Nicol K, Batra R. Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol. 2004;5(6):417\u201322. https:\/\/doi.org\/10.2165\/00128071-200405060-00006.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1351_CR51","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40257-015-0133-9","volume":"16","author":"SZ Ghodsi","year":"2015","unstructured":"Ghodsi SZ, Abbas Z, Abedeni R. Efficacy of oral itraconazole in the treatment and relapse prevention of moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial. Am J Clin Dermatol. 2015;16(5):431\u20137. https:\/\/doi.org\/10.1007\/s40257-015-0133-9.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1351_CR52","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s10227-001-0048-3","volume":"6","author":"AK Gupta","year":"2002","unstructured":"Gupta AK, Chwetzoff E, Del Rosso J, Baran R. Hepatic safety of itraconazole. J Cutan Med Surg. 2002;6(3):210\u20133. https:\/\/doi.org\/10.1007\/s10227-001-0048-3.","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"1351_CR53","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/ijd.16582","volume":"62","author":"Z Yanfei","year":"2023","unstructured":"Yanfei Z, Xiaoying N, Dingwei Z, Wei W, Jianwen R. Efficacy and safety of oral isotretinoin in the treatment of moderate to severe seborrheic dermatitis: a retrospective study. Int J Dermatol. 2023;62(6):759\u201363. https:\/\/doi.org\/10.1111\/ijd.16582.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1351_CR54","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/1203475419878162","volume":"24","author":"SR Cohen","year":"2020","unstructured":"Cohen SR, Gordon SC, Lam AH, Rosmarin D. Recalcitrant seborrheic dermatitis successfully treated with apremilast. J Cutan Med Surg. 2020;24(1):90\u20131. https:\/\/doi.org\/10.1177\/1203475419878162.","journal-title":"J Cutan Med Surg"},{"issue":"10","key":"1351_CR55","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1007\/s00403-023-02680-9","volume":"315","author":"S Ghalili","year":"2023","unstructured":"Ghalili S, David E, Ungar B, et al. IL-12\/23-targeting in seborrheic dermatitis patients leads to long-lasting response. Arch Dermatol Res. 2023;315(10):2937\u201340. https:\/\/doi.org\/10.1007\/s00403-023-02680-9.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"1351_CR56","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/2772434416666211029113213","volume":"16","author":"A Ayatollahi","year":"2021","unstructured":"Ayatollahi A, Firooz A, Lotfali E, Mojab F, Fattahi M. Herbal therapy for the management of seborrheic dermatitis: a narrative review. Recent Adv Antiinfect Drug Discov. 2021;16(3):209\u201326. https:\/\/doi.org\/10.2174\/2772434416666211029113213.","journal-title":"Recent Adv Antiinfect Drug Discov"},{"issue":"11","key":"1351_CR57","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1111\/jocd.15818","volume":"22","author":"F Zhang","year":"2023","unstructured":"Zhang F, Li YH, Ren W, Li SR, Chen YC. Clinical efficacy of a combination treatment of traditional Chinese medicine for scalp seborrheic dermatitis. J Cosmet Dermatol. 2023;22(11):3072\u20137. https:\/\/doi.org\/10.1111\/jocd.15818.","journal-title":"J Cosmet Dermatol"},{"issue":"12","key":"1351_CR58","doi-asserted-by":"publisher","first-page":"e12338","DOI":"10.1016\/j.heliyon.2022.e12338","volume":"8","author":"R Zhang","year":"2022","unstructured":"Zhang R, Nie Y, Wang Y, Zhai X, Zhu J, Duan Y. Effectiveness of traditional Chinese medicine preparations for facial seborrheic dermatitis: case reports. Heliyon. 2022;8(12):e12338. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e12338.","journal-title":"Heliyon"},{"issue":"3","key":"1351_CR59","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3831\/KPI.2024.27.3.264","volume":"27","author":"Y Pak","year":"2024","unstructured":"Pak Y, Shin S. Seborrheic dermatitis treatment using a standardized medical insurance-approved Korean medicine: a case report. J Pharmacopuncture. 2024;27(3):264\u20139. https:\/\/doi.org\/10.3831\/KPI.2024.27.3.264.","journal-title":"J Pharmacopuncture"},{"issue":"10","key":"1351_CR60","doi-asserted-by":"publisher","first-page":"819","DOI":"10.36849\/JDD.2024.8116","volume":"23","author":"D Jaalouk","year":"2024","unstructured":"Jaalouk D, Pulumati A, Algarin YA, Kircik L, Issa NT. Dermatologic procedures for the treatment of seborrheic dermatitis. J Drugs Dermatol. 2024;23(10):819\u201324. https:\/\/doi.org\/10.36849\/JDD.2024.8116.","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"1351_CR61","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1111\/jocd.15957","volume":"22","author":"R Kapoor","year":"2023","unstructured":"Kapoor R, Shome D, Doshi K, Patel G, Tandel H, Kumar V. A newer approach in the treatment of seborrheic dermatitis with QR678\u00ae and QR678 Neo\u00ae\u2014a prospective pilot study. J Cosmet Dermatol. 2023;22(11):3078\u201387. https:\/\/doi.org\/10.1111\/jocd.15957.","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"1351_CR62","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1046\/j.1365-2133.2000.03828.x","volume":"143","author":"D Pirkhammer","year":"2000","unstructured":"Pirkhammer D, Seeber A, H\u00f6nigsmann H, Tanew A. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrheic dermatitis. Br J Dermatol. 2000;143(5):964\u20138. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03828.x.","journal-title":"Br J Dermatol"},{"key":"1351_CR63","doi-asserted-by":"publisher","first-page":"e1875","DOI":"10.6061\/clinics\/2020\/e1875","volume":"75","author":"RL Gu","year":"2020","unstructured":"Gu RL, Wang SQ. Clinical study on treatment of facial seborrheic dermatitis with intense pulsed light combined with 30% supramolecular salicylic acid. Clinics (Sao Paulo). 2020;75:e1875. https:\/\/doi.org\/10.6061\/clinics\/2020\/e1875.","journal-title":"Clinics (Sao Paulo)"},{"issue":"2","key":"1351_CR64","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4103\/JCAS.JCAS_188_20","volume":"14","author":"S Fonseka","year":"2021","unstructured":"Fonseka S, Narankotuwa KHH, Bandara DDJ. Light-emitting diode light therapy for facial seborrhoeic dermatitis: a case report. J Cutan Aesthet Surg. 2021;14(2):241\u20133. https:\/\/doi.org\/10.4103\/JCAS.JCAS_188_20.","journal-title":"J Cutan Aesthet Surg"},{"issue":"1","key":"1351_CR65","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/jdv.12070","volume":"28","author":"SH Kwon","year":"2014","unstructured":"Kwon SH, Jeong MY, Park KC, Youn SW, Huh CH, Na JI. A new therapeutic option for facial seborrheic dermatitis: indole-3-acetic acid photodynamic therapy. J Eur Acad Dermatol Venereol. 2014;28(1):94\u20139. https:\/\/doi.org\/10.1111\/jdv.12070.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1351_CR66","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1111\/jocd.14414","volume":"21","author":"J Liu","year":"2022","unstructured":"Liu J, Han C, Feng X, Liang J, Qu Y. Effective picosecond Nd:YAG laser on seborrheic dermatitis and its mechanism. J Cosmet Dermatol. 2022;21(6):2449\u201357. https:\/\/doi.org\/10.1111\/jocd.14414.","journal-title":"J Cosmet Dermatol"},{"issue":"1","key":"1351_CR67","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/DSS.0000000000003960","volume":"50","author":"YG Choi","year":"2024","unstructured":"Choi YG, Kim SY, Kim JS, Choi YJ, Kim WS. Efficacy and safety of precision cryotherapy to treat seborrheic dermatitis of the scalp. Dermatol Surg. 2024;50(1):47\u201351. https:\/\/doi.org\/10.1097\/DSS.0000000000003960.","journal-title":"Dermatol Surg"},{"key":"1351_CR68","doi-asserted-by":"publisher","first-page":"555824","DOI":"10.3389\/fmed.2020.555824","volume":"7","author":"X Zhang","year":"2020","unstructured":"Zhang X, Luo B, Mo H, et al. Clinical evaluation of sequential transdermal delivery of vitamin\u00a0B6, compound glycyrrhizin, metronidazole, and hyaluronic acid using needle-free liquid jet in facial seborrheic dermatitis. Front Med (Lausanne). 2020;7:555824. https:\/\/doi.org\/10.3389\/fmed.2020.555824.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"1351_CR69","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s13555-024-01161-9","volume":"14","author":"MT Polaskey","year":"2024","unstructured":"Polaskey MT, Woolery-Llloyd H, Osborne D, Burnett P, Hanna D, Chovatiya R. When patient diversity informs formulation: reimagining treatment for seborrheic dermatitis. Dermatol Ther (Heidelb). 2024;14(5):1071\u20137. https:\/\/doi.org\/10.1007\/s13555-024-01161-9.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"1351_CR70","doi-asserted-by":"publisher","first-page":"e48782","DOI":"10.7759\/cureus.48782","volume":"15","author":"M Alshaebi","year":"2023","unstructured":"Alshaebi M, Zahed L, Osaylan M, et al. Association between diet and seborrheic dermatitis: a case-control study. Cureus. 2023;15(11):e48782. https:\/\/doi.org\/10.7759\/cureus.48782.","journal-title":"Cureus"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01351-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01351-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01351-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T08:04:26Z","timestamp":1741939466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01351-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1351"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01351-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Savanna I Vidals work is funded through an independent research grant from Galderma. Nikita Mentas work is funded through independent research grants from Incyte and Johnson & Johnson. Lawrence Green is an investigator, speaker or advisor to Amgen, Arcutis, BMS, Dermavant\/Organaon, Incyte, Janssen, Pfizer, UCB, OrthoDerm, Vyne, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies performed by any of the authors with human participants nor animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}